Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
VALNEVA Saint-Herblain (France), January 10, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evalu...